66521-70-8 Usage
Description
4-(4-PYRIDINYL)-2-PYRIMIDINAMINE is an organic compound that serves as an intermediate in the synthesis of Imidazolylbenzene derivatives and analogs. It plays a crucial role in the development of PCSK9 inhibitors, which are important for managing cholesterol levels and preventing cardiovascular diseases.
Uses
Used in Pharmaceutical Industry:
4-(4-PYRIDINYL)-2-PYRIMIDINAMINE is used as a key intermediate in the synthesis of Imidazolylbenzene derivatives and analogs for their application as PCSK9 inhibitors. These inhibitors help in reducing low-density lipoprotein cholesterol (LDL-C) levels, which is a significant risk factor for cardiovascular diseases. By targeting PCSK9, these inhibitors can potentially offer a novel therapeutic approach for the treatment and prevention of atherosclerosis and related conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 66521-70-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,6,5,2 and 1 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 66521-70:
(7*6)+(6*6)+(5*5)+(4*2)+(3*1)+(2*7)+(1*0)=128
128 % 10 = 8
So 66521-70-8 is a valid CAS Registry Number.
66521-70-8Relevant articles and documents
Preparation method and application of N-(pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor
-
Paragraph 0223; 0227-0229; 0232; 0235-0237, (2020/12/14)
The invention discloses a cyclin-dependent kinase inhibitor. The cyclin-dependent kinase inhibitor comprises an N-(pyrimidine-2-yl) coumarin-7-amine derivative shown as a general formula (I). In-vitropharmacodynamic tests prove that the compound has a high-selectivity inhibition effect on CDK9 kinase, and can be applied to reducing or inhibiting the activity of CDK9 kinase in cells. The inventionalso discloses a preparation method of the inhibitor and application of the inhibitor in drugs for CDK family kinase mediated diseases, especially hyperproliferative diseases, virus-induced infectious diseases and cardiovascular diseases.
